Testing the Addition of Herceptin Hylecta or Phesgo to the Usual Chemotherapy for HER2 Positive Endometrial Serous Carcinoma or Carcinosarcoma
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Astellas Pharma Inc
Inhibrx Biosciences, Inc
Tyligand Pharmaceuticals (Suzhou) Limited
University of Kentucky
Merck Sharp & Dohme LLC
Trishula Therapeutics, Inc.